Published on : May 11, 2015
In a step taken towards expansion of operation, Alexion is gearing up to make a huge investment amounting to €450m for the construction of a new manufacturing facility. This facility will be located at the College Park, near Blanchardstown.
During the phase of development, which spanned over four years eight hundred temporary engineering and construction positions will be created. The plant will be an expansive one, spreading over twenty thousand square meters and will be dedicated to the production of biologic drugs administered for the treatment of rare and severe ailments. This huge manufacturing unit, will the first of the company’s plants dedicated to biologics manufacturing located outside the United States.
Only last year, the company had announced its plans for investing €55 million in a facility dedicated to the manufacturing of vial filling to be located in Athlone, and another worth €75 million, which will is slated to be a global supply chain headquarter and the location for the facility was the same site, that is, Blanchardstown.
Construction is continuing simultaneously in both the locations. An insider from the company revealed, once the construction of all these three facilities is completed, Alexion will create 500 vacancies for the permanent staffs across these facilities.
In a similar project, the company also invested in Ireland, back in 2013, and today the facility has over 170 permanent staffs working in different positions.
The investment was supported by the Department of Jobs, Enterprise and Innovation in collaboration with IDA Ireland. The developments spurred by the facility in Ireland, was welcomes by Richard Bruton, who is the Minister of Jobs, and also by Tánaiste Joan Burton.
Alexion originally is a Connecticut based company, and is renowned for manufacturing a wide range of drugs hugely administered across economies to treat people suffering for severe and rare ailments such as Hemolytic-uremic syndrome and Paroxysmal nocturnal hemoglobinuria.